Virus Products

Viral Vectors for CAR

The history of CAR technology dates back to the 1960s when scientists discovered that immune system cells could kill cancer cells. In 1993, the first CAR design was developed, followed by several generations of improvements, notably the introduction of co-stimulatory signaling domains in 1998, which significantly enhanced the antitumor activity of CAR-T cells. In 2017, the emergence of the first CAR-T cell therapy marked a breakthrough in this field.

Fig. 1 CAR-T cell therapy milestones.¹

Viral vectors have efficient gene transduction capabilities, enabling the effective introduction of CAR genes into T cells. This high transduction efficiency is key to the successful generation of CAR-T cells.

The application of viral vectors in CAR-T cell therapy presents several advantages. Viral vectors, such as retroviruses and lentiviruses, are capable of effectively delivering CAR genes into T cells, which enhances the efficiency of CAR-T cell production. All CAR-T cell therapies utilize these viral vectors, demonstrating their effectiveness in clinical settings. The use of viral vectors has been refined over many years of research and development, resulting in a relatively mature technology that supports the production and application of CAR-T cells.

Off-the-Shelf Plasmid Products at Creative Biolabs

Off-the-Shelf plasmids are pre-prepared and suitable for large-scale production, thereby reducing production time and improving cost-effectiveness and efficiency. Furthermore, the standardized production process ensures consistency in plasmid quality, enhancing the reliability and safety of CAR-T cell products. To address urgent needs, Off-the-Shelf plasmids can be quickly utilized for CAR-T cell production. Additionally, due to the standardization and consistency of the plasmids, regulatory approval processes can be simplified, accelerating product launch. Off-the-Shelf plasmids enable users to make rapid adjustments and applications according to different requirements, making them an important choice in developing CAR-T cell therapies.

Key Features

Creative Biolabs' Off-the-Shelf plasmids represent a convenient and high-quality solution for researchers engaged in gene and cell therapy development. We offer a range of Off-the-Shelf products, specifically GMP-like and GMP-grade plasmids. These plasmids are manufactured in advanced facilities and are optimized to ensure high viral yields.

For more GMP Products, please click on the categories below:

• Viral Vector Plasmid
• Virus Products

Reference

1. Uscanga-Palomeque, A. C., et al. "CAR-T Cell Therapy: From the Shop to Cancer." International journal of molecular sciences 24.21 (2023): 15688. Distributed under Open Access license CC BY 4.0, without modification.